The Worley Ltd (ASX: WOR) share price is in focus after the company flagged a potential hit of up to $60 million to FY26 underlying EBITA from ongoing Middle East conflict disruptions, alongside a $50 million foreign currency translation impact expected in the same period.

What did Worley report?

• No cancellations of Middle East projects to date, but new project starts and awards continue to be delayed
• FY26 underlying EBITA impact now forecast up to $60 million (previously $30–$40 million)
• Additional $50 million estimated translation impact on FY26 underlying EBITA from stronger Australian dollar
• Update reflects increased uncertainty and extended conflict duration in the region

What else do investors need to know?

The Middle East conflict continues to disrupt the progress of Worley’s existing projects across the region, with customer delays on commencing and awarding new projects. While no contracts have been cancelled, ongoing delays are expected to weigh on upcoming financial performance.

Worley also advised that the stronger Australian dollar in the second half of FY26 will reduce the contribution from overseas earnings when translated back into Australian dollars, compounding the previously announced operational impacts. The estimate of foreign currency translation effects remains subject to further exchange rate movements throughout the year.

What’s next for Worley?

Looking ahead, Worley continues to monitor the evolving geopolitical situation. While recent diplomatic developments in the Middle East show some promise, the company remains cautious, acknowledging ongoing uncertainty regarding project timing and regional stability. Management is actively supporting customers and staff in affected regions and adapting resource planning and contract strategies to manage risks.

Worley’s broader strategy focuses on maintaining operational resilience and leveraging its global footprint through diversified service offerings. The company says it is committed to supporting customers as they navigate current disruptions and transition towards more sustainable solutions in the longer term.

Worley share price snapshot

Over the past 12 months, Worley shares have declined 6%, trailing the S&P/ASX 200 Index (ASX: XJO), which has risen 3% over the same period.

View Original Announcement

The post Worley flags FY26 earnings hit from Middle East delays and currency impact appeared first on The Motley Fool Australia.

More reading

• Lendlease Group shares paused pending further announcement
• Corporate Travel Management updates investors on delayed FY25 results and UK remediation
• Pro Medicus signs Echo IQ deal to boost AI cardiology offering
• Ventia Services appoints new CEO in leadership succession
• A2 Milk declares $300 million special dividend after securing China approval

Motley Fool contributor Laura Stewart has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips. This article was prepared with the assistance of Large Language Model (LLM) tools for the initial summary of the company announcement. Any content assisted by AI is subject to our robust human-in-the-loop quality control framework, involving thorough review, substantial editing, and fact-checking by our experienced writers and editors holding appropriate credentials. The Motley Fool Australia stands behind the work of our editorial team and takes ultimate responsibility for the content published by The Motley Fool Australia.

Telix Pharmaceuticals Ltd (ASX: TLX) shares have been gaining momentum in 2026.

The ASX healthcare share is up 18% over the past month and 40% since the start of the year. While the stock remains down 36% over the past 12 months, investors have become increasingly optimistic about the company’s prospects.

That renewed confidence appears to extend well beyond retail investors.

According to an ASX filing released today, global investment giant Vanguard Group recently acquired 17.7 million Telix shares, lifting its voting power to 5.2%.

The sizeable position suggests Vanguard sees value in the healthcare company despite its strong recent rally.

Why are Telix shares attracting attention?

Telix specialises in radiopharmaceuticals, a fast-growing area of healthcare that combines targeted imaging and therapeutic technologies to help diagnose and treat diseases such as cancer.

The company has built expertise across research, development, manufacturing, and commercialisation, creating significant barriers to entry for potential competitors.

Developing radiopharmaceutical products requires specialised facilities, regulatory approvals, and distribution capabilities that are difficult and expensive to replicate.

That gives Telix shares a competitive advantage in a market expected to experience strong long-term growth.

Positive news flow continues

Investor sentiment has improved considerably in recent months following a series of encouraging announcements.

In late February, Telix secured a key regulatory approval filing in Europe, an important milestone as the company expands its commercial footprint internationally.

Momentum continued in April when the company announced that the US Food and Drug Administration had accepted its New Drug Application for TLX101-Px (Pixclara®).

The FDA’s acceptance represents a significant step towards potential commercialisation and broadened the company’s pipeline opportunities.

These developments have helped rebuild investor confidence following a challenging period for Telix shares.

Strong financial performance

The company’s financial results have also strengthened the investment case.

In April, Telix reported first-quarter 2026 group revenue of US$230 million. That represented an 11% increase on the previous quarter and a 23.7% rise compared to the prior corresponding period.

Management of Telix shares continues to guide for strong growth, supported by its expanding Precision Medicine business and a growing portfolio of radiopharmaceutical products.

Importantly, the company continues to invest heavily in research and development, helping advance multiple late-stage programs and future growth opportunities.

Vanguard and analysts see further upside

Vanguard is not alone in its optimism.

According to TradingView data, the majority of analysts covering the ASX healthcare share currently rate it as a strong buy.

The most bullish price target stands at $31.64 per share, implying potential upside of approximately 101% from current levels.

Meanwhile, Morgans has a $24.33 price target on the stock, suggesting upside of around 55%.

While no investment is without risk, Vanguard’s decision to build a sizeable position suggests one of the world’s largest fund managers believes Telix’s growth story is far from over.

The post Why this top investor is snapping up millions of Telix shares appeared first on The Motley Fool Australia.

More reading

• 3 reasons to buy this recovering ASX healthcare share
• Here are the top 10 ASX 200 shares today
• Here are the top 10 ASX 200 shares today
• 2 ASX growth shares that could double your money
• Here are the 10 most shorted ASX shares

Motley Fool contributor Marc Van Dinther has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Telix Pharmaceuticals. The Motley Fool Australia has recommended Telix Pharmaceuticals. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

The Pro Medicus Ltd (ASX: PME) share price is in focus after the company announced a binding Heads of Agreement with Echo IQ for a finance facility and reseller agreement, aiming to expand its AI-driven cardiology solutions.

What did Pro Medicus report?

• Signed a binding Heads of Agreement with Echo IQ Ltd for a financing arrangement
• Agreement includes a reseller arrangement for Echo IQ’s AI algorithms in cardiology
• Focus on commercialising solutions for aortic stenosis and heart failure detection
• Definitive agreements expected within 20 business days or the transaction may lapse

What else do investors need to know?

Pro Medicus is broadening its AI strategy by adding third-party algorithms to its Visage 7 Cardiology platform, alongside in-house and partner-developed solutions. The finance facility for Echo IQ is designed to help accelerate its AI offerings, particularly in key disease areas.

While the Heads of Agreement sets out the framework, the deal is subject to final legal agreements. Pro Medicus has committed to updating shareholders once these are completed or if negotiations end without a deal.

What did Pro Medicus management say?

Chief Executive Officer Dr Sam Hupert said:

In addition to providing financial backing, we are looking to offer our Visage 7 Cardiology customers the option of Echo IQ’s technology. This is in line with our AI strategy of offering a curated suite of algorithms that will be a mixture of algorithms created by us, those created in conjunction with our clinical partners and 3rd party algorithms such as Echo-IQ.

What’s next for Pro Medicus?

Pro Medicus plans to proceed with negotiating definitive agreements with Echo IQ over the next 20 business days. The move supports its ambition to grow market offerings and provide innovative, AI-powered cardiology solutions to its customers.

If successful, the agreement will further expand Pro Medicus’ AI capabilities and commercial reach, reinforcing its growth strategy in health imaging.

Pro Medicus share price snapshot

Over the past 12 months, Pro Medicus shares have declined 35%, trailing the S&P/ASX 200 Index (ASX: XJO), which has risen 3% over the same period.

View Original Announcement

The post Pro Medicus signs Echo IQ deal to boost AI cardiology offering appeared first on The Motley Fool Australia.

More reading

• Ventia Services appoints new CEO in leadership succession
• A2 Milk declares $300 million special dividend after securing China approval
• 2 ASX 200 shares I’d buy for powerful growth
• 5 things to watch on the ASX 200 on Thursday
• 3 buy-rated ASX tech shares with bright futures

Motley Fool contributor Laura Stewart has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has recommended Pro Medicus. The Motley Fool Australia has recommended Pro Medicus. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips. This article was prepared with the assistance of Large Language Model (LLM) tools for the initial summary of the company announcement. Any content assisted by AI is subject to our robust human-in-the-loop quality control framework, involving thorough review, substantial editing, and fact-checking by our experienced writers and editors holding appropriate credentials. The Motley Fool Australia stands behind the work of our editorial team and takes ultimate responsibility for the content published by The Motley Fool Australia.